Literature DB >> 14747443

The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas.

N D Stafford1, L T Condon, M J C Rogers, L Helboe, D A Crooks, S L Atkin.   

Abstract

AIMS: Acoustic neuroma is a benign tumour, which develops through an overproliferation of Schwann cells along the vestibular nerve. Somatostatin is a naturally occurring peptide, which exerts antiproliferative and antiangiogenic effects via five membrane bound receptor subtypes. The aim of this study was to determine whether somatostatin receptor subtypes (SSTRs) 1, 2, 3, and 5 are present in acoustic neuromas.
METHODS: The expression of SSTRs 1, 2, 3, and 5 was studied in both the Schwann cells and blood vessels of eight acoustic neuroma specimens, by means of immunohistochemistry using novel rabbit polyclonal antibodies raised against human SSTR 1, 2, and 5 subtype specific peptides, and a commercial anti-SSTR3 antibody.
RESULTS: SSTR2 was the most prevalent subtype in Schwann cells (seven of eight), with intermediate expression of SSTR3 (six of eight), and lower expression of SSTRs 1 and 5 (four of eight and five of eight, respectively). There was ubiquitous vascular expression of SSTR2, with no evidence of SSTR 1, 3, or 5 expression in blood vessels.
CONCLUSION: SSTRs 1, 2, 3, and 5 are differentially expressed in acoustic neuromas. Somatostatin analogues may have a therapeutic role in the management of this rare and challenging condition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747443      PMCID: PMC1770210          DOI: 10.1136/jcp.2003.007260

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  22 in total

Review 1.  The future of somatostatin analogue therapy.

Authors:  P M Stewart; R A James
Journal:  Baillieres Best Pract Res Clin Endocrinol Metab       Date:  1999-10

Review 2.  Molecular genetics of acoustic tumors.

Authors:  M J Lanser
Journal:  Otolaryngol Clin North Am       Date:  1992-10       Impact factor: 3.346

3.  PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.

Authors:  M Henze; J Schuhmacher; P Hipp; J Kowalski; D W Becker; J Doll; H R Mäcke; M Hofmann; J Debus; U Haberkorn
Journal:  J Nucl Med       Date:  2001-07       Impact factor: 10.057

4.  Intracanalicular acoustic neuromas: the case for early surgery.

Authors:  R T Ramsden; D A Moffat
Journal:  Clin Otolaryngol Allied Sci       Date:  1994-02

Review 5.  The neurobiology of somatostatin.

Authors:  J Epelbaum; P Dournaud; M Fodor; C Viollet
Journal:  Crit Rev Neurobiol       Date:  1994

6.  Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A.

Authors:  S Schulz; S U Pauli; S Schulz; M Händel; K Dietzmann; R Firsching; V Höllt
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

Review 7.  Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.

Authors:  R Arnold; B Simon; M Wied
Journal:  Digestion       Date:  2000       Impact factor: 3.216

Review 8.  Somatostatin receptors.

Authors:  N Benali; G Ferjoux; E Puente; L Buscail; C Susini
Journal:  Digestion       Date:  2000       Impact factor: 3.216

9.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728

10.  Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth.

Authors:  J W Koper; R Markstein; C Kohler; D J Kwekkeboom; C J Avezaat; S W Lamberts; J C Reubi
Journal:  J Clin Endocrinol Metab       Date:  1992-03       Impact factor: 5.958

View more
  3 in total

1.  Expression of estrogen and progesterone receptors in vestibular schwannomas and their clinical significance.

Authors:  Sushila Jaiswal; Vinita Agrawal; Awadhesh Kumar Jaiswal; Rakesh Pandey; Ashok Kumar Mahapatra
Journal:  J Negat Results Biomed       Date:  2009-11-04

2.  Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.

Authors:  Sunil Bhandari; Neil Watson; Ervine Long; Steve Sharpe; Wenwen Zhong; Shang-Zhong Xu; Stephen L Atkin
Journal:  J Histochem Cytochem       Date:  2008-04-28       Impact factor: 2.479

3.  Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium.

Authors:  R L Adams; I P Adams; S W Lindow; W Zhong; S L Atkin
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.